NO323757B1 - Diagnostiske midler for pankreasksokrin funksjon i en pustetest, samt 13C- eller 14C-merket forbindelse eller salt. - Google Patents

Diagnostiske midler for pankreasksokrin funksjon i en pustetest, samt 13C- eller 14C-merket forbindelse eller salt. Download PDF

Info

Publication number
NO323757B1
NO323757B1 NO19992727A NO992727A NO323757B1 NO 323757 B1 NO323757 B1 NO 323757B1 NO 19992727 A NO19992727 A NO 19992727A NO 992727 A NO992727 A NO 992727A NO 323757 B1 NO323757 B1 NO 323757B1
Authority
NO
Norway
Prior art keywords
leu
ala
amino acid
gly
phe
Prior art date
Application number
NO19992727A
Other languages
English (en)
Norwegian (no)
Other versions
NO992727D0 (no
NO992727L (no
Inventor
Tadashi Kohno
Iasaburo Hosoi
Junko Ohshima
Kunihiko Shibata
Asuka Ito
Original Assignee
Tokyo Gas Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tokyo Gas Co Ltd filed Critical Tokyo Gas Co Ltd
Publication of NO992727D0 publication Critical patent/NO992727D0/no
Publication of NO992727L publication Critical patent/NO992727L/no
Publication of NO323757B1 publication Critical patent/NO323757B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1206—Administration of radioactive gases, aerosols or breath tests
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A61K49/1815—Suspensions, emulsions, colloids, dispersions compo-inhalant, e.g. breath tests
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Atmospheric Sciences (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Obesity (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO19992727A 1998-06-05 1999-06-04 Diagnostiske midler for pankreasksokrin funksjon i en pustetest, samt 13C- eller 14C-merket forbindelse eller salt. NO323757B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP15785598 1998-06-05
JP14949699A JP3340699B2 (ja) 1998-06-05 1999-05-28 膵外分泌機能診断剤

Publications (3)

Publication Number Publication Date
NO992727D0 NO992727D0 (no) 1999-06-04
NO992727L NO992727L (no) 1999-12-06
NO323757B1 true NO323757B1 (no) 2007-07-02

Family

ID=26479372

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19992727A NO323757B1 (no) 1998-06-05 1999-06-04 Diagnostiske midler for pankreasksokrin funksjon i en pustetest, samt 13C- eller 14C-merket forbindelse eller salt.

Country Status (10)

Country Link
EP (1) EP0966975B1 (de)
JP (1) JP3340699B2 (de)
AU (1) AU729896B2 (de)
CA (1) CA2273549C (de)
DE (1) DE69927089T2 (de)
DK (1) DK0966975T3 (de)
ES (1) ES2249873T3 (de)
NO (1) NO323757B1 (de)
NZ (1) NZ336116A (de)
PT (1) PT966975E (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6284219B1 (en) 1998-06-30 2001-09-04 Phenome Sciences Inc. In vivo determination of metabolic function for use in therapy management
JP2001139498A (ja) * 1999-11-15 2001-05-22 Tokyo Gas Co Ltd 膵外分泌機能診断剤
US7232559B1 (en) * 1999-06-04 2007-06-19 Tokyo Gas Company Limited Diagnostic agents for pancreatic exocrine function
US7125683B2 (en) * 2000-09-07 2006-10-24 Tokyo Gas Company Limited Preparations for diagnosis extrapancreatic secretory function
PT1424083E (pt) 2001-08-10 2007-01-31 Tokyo Gas Co Ltd Agente diagnóstico da função exócrina pancreática
US7781396B2 (en) 2002-01-31 2010-08-24 Tel Aviv University Future Technology Development L.P. Peptides directed for diagnosis and treatment of amyloid-associated disease
MXPA04008180A (es) 2002-02-21 2005-05-16 Tokyo Gas Co Ltd Reactivo de diagnostico para evaluacion de efecto farmacologico de medicina, y metodo y reactivo para seleccionar agentes farmaceuticos que comprenden enzima, inhibidor de enzima o ligando receptor y/o promedicamentos del mismo para uno que tiene alt
AU2003212893A1 (en) 2002-02-27 2003-09-09 Cambridge Isotope Laboratories, Inc. Use of 13C labelled substance for measuring lung fuction
US7491699B2 (en) 2002-12-09 2009-02-17 Ramot At Tel Aviv University Ltd. Peptide nanostructures and methods of generating and using the same
EP1583713B1 (de) 2003-01-07 2009-03-25 Ramot at Tel Aviv University Ltd. Peptidenanostrukturen die fremdmaterial enthalten, und verfahren zur herstellung derselben
CN101415724B (zh) 2003-06-30 2015-12-02 特拉维夫大学未来科技开发有限公司 肽、抗肽抗体以及用它们来诊断和治疗淀粉样蛋白相关疾病的方法
WO2005027901A1 (en) 2003-09-25 2005-03-31 Tel Aviv University Future Technology Development L.P. Compositions and methods using same for treating amyloid-associated diseases
WO2005031362A2 (en) 2003-10-02 2005-04-07 Ramot At Tel Aviv University Ltd. Novel antibacterial agents and methods of identifying and utilizing same
WO2006013552A2 (en) 2004-08-02 2006-02-09 Ramot At Tel Aviv University Ltd. Articles of peptide nanostructures and method of forming the same
US7732479B2 (en) 2004-08-19 2010-06-08 Tel Aviv University Future Technology Development L.P. Compositions for treating amyloid associated diseases
US7786086B2 (en) 2004-09-08 2010-08-31 Ramot At Tel-Aviv University Ltd. Peptide nanostructures containing end-capping modified peptides and methods of generating and using the same
WO2006068768A2 (en) 2004-11-24 2006-06-29 Hanna Skubatch Methods and compositions for treating conditions
EP1973928A2 (de) 2005-10-11 2008-10-01 Ramot at Tel-Aviv University Ltd. Selbstzusammengebaute fmoc-ff-hydrogele
US7879212B2 (en) 2005-11-03 2011-02-01 Ramot At Tel-Aviv University Ltd. Peptide nanostructure-coated electrodes
US7557088B2 (en) 2006-03-28 2009-07-07 Neopro Labs, Llc Methods and compositions for treating conditions
US8217141B2 (en) 2007-05-17 2012-07-10 Neopro Labs, Llc Crystalline and amorphous forms of peptide
TR2021004329A2 (tr) * 2021-03-05 2022-09-21 Argeron Medikal Arastirma Sanayi Ve Ticaret Anonim Sirketi Bi̇yoki̇myasal tibbi̇ tani ki̇ti̇
CA3213636A1 (en) 2021-03-18 2022-09-22 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4279886A (en) * 1979-01-02 1981-07-21 University Patents, Inc. Test for pancreatic exocrine function
US4676974A (en) * 1984-05-17 1987-06-30 The Regents Of The University Of California Breath test for pancreatic exocrine function
US5506147A (en) 1993-04-15 1996-04-09 Kolhouse; J. Fred Non-invasive evaluation of maldigestion and malaborption
DE69819478T2 (de) * 1997-02-03 2004-09-02 Mallinckrodt, Inc. Verfahren zum Nachweis und zur Lokalisierung maligner menschlicher Pankreastumore
US6284219B1 (en) * 1998-06-30 2001-09-04 Phenome Sciences Inc. In vivo determination of metabolic function for use in therapy management
NZ507949A (en) * 1998-09-25 2002-03-01 Tokyo Gas Co Ltd C-13 or C-14 labelled fluorescein derivatives and diagnostic compositions
JP2001139498A (ja) * 1999-11-15 2001-05-22 Tokyo Gas Co Ltd 膵外分泌機能診断剤

Also Published As

Publication number Publication date
DK0966975T3 (da) 2005-10-03
EP0966975A3 (de) 2002-04-17
ES2249873T3 (es) 2006-04-01
DE69927089D1 (de) 2005-10-13
EP0966975B1 (de) 2005-09-07
CA2273549A1 (en) 1999-12-05
NO992727D0 (no) 1999-06-04
AU3316899A (en) 1999-12-16
AU729896B2 (en) 2001-02-15
EP0966975A2 (de) 1999-12-29
PT966975E (pt) 2005-11-30
JP2000053697A (ja) 2000-02-22
JP3340699B2 (ja) 2002-11-05
DE69927089T2 (de) 2006-05-18
CA2273549C (en) 2006-10-24
NO992727L (no) 1999-12-06
NZ336116A (en) 2000-10-27

Similar Documents

Publication Publication Date Title
CA2273549C (en) Diagnostic agents for pancreatic exocrine function
US9999689B2 (en) Imaging beta cell mass
BRPI0717135A2 (pt) Antagonistas de receptores (sstr2) seletivos de so-mastotatina
Adibi et al. Influence of molecular structure on half-life and hydrolysis of dipeptides in plasma: importance of glycine as N-terminal amino acid residue
US6156346A (en) Urease-responsive delivery systems for diagnostic and therapeutic applications
JP5448397B2 (ja) 基質プローブ、多重核磁気共鳴法による酵素活性の検出方法および酵素活性のイメージング方法
AU2003303714B2 (en) Improved linkers for radiopharmaceutical compounds
EP3710068A1 (de) Doppelmarkierte sonde zur molekularen bildgebung und deren verwendung
JP5503498B2 (ja) 膵島イメージング用分子プローブ前駆体及びその使用
IE911649A1 (en) Novel derivatives of endogenous mediators, their salts, method of preparation, applications and compositions in which they are present
CN118852348A (zh) 靶向碳酸酐酶ix的肽配体、包含其的肽结构体及它们的用途
CN102369015A (zh) 肽、包含该肽的药物组合物及其用途
EP1101499A2 (de) Diagnostika für die exokrine Pankreasfunktion
US20050191240A1 (en) Labeled neurotensin derivatives
US7232559B1 (en) Diagnostic agents for pancreatic exocrine function
US20080139479A1 (en) Bladder tumor-targeting peptide and use thereof
US20050112064A1 (en) DNA-dependent MRI contrast agents
US7662857B2 (en) Diagnostic agents for pancreatic exocrine function
Garg et al. Stimulation of gallbladder by intravenous infusion of amino acid: a new method to obtain duodenal bile for bile analyses
CN101951964A (zh) 成像方法
Ollenschläger et al. Amino acid determination of human intestinal mucosa obtained by endosopic biopsies
Deshpande et al. Mapping the binding site of tissue kallikrein: preparation and testing of all possible substrate analog inhibitors homologous with the sequence of kininogen between Ser386 and Gln392
JP2003128693A (ja) 膵外分泌機能診断剤
JP4076732B2 (ja) Ｄ−アスパラギン酸エンドペプチダーゼ活性を阻害する化合物
CN120865334A (zh) 一种靶向软骨的阳离子肽类化合物及其制备方法与应用

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees